Skip to main content
Top

Open Access 10-04-2024 | Acute Lymphoblastic Leukemia | RESEARCH ARTICLE

ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

Authors: Antonio Juan-Ribelles, Francisco Bautista, Adela Cañete, Alba Rubio-San-Simón, Anna Alonso-Saladrigues, Raquel Hladun, Susana Rives, Jose Luís Dapena, Jose María Fernández, Álvaro Lassaletta, Ofelia Cruz, Gemma Ramírez-Villar, Jose Luís Fuster, Cristina Diaz de Heredia, Miguel García-Ariza, Eduardo Quiroga, María del Mar Andrés, Jaime Verdú-Amorós, Antonio Molinés, Blanca Herrero, Mónica López, Catalina Márquez, María Toboso, Frencisco Lendínez, Jose Gómez Sirvent, María Tallón, Guiomar Rodríguez, Tomás Acha, Lucas Moreno, Ana Fernández-Teijeiro, the Sociedad Española de Hematología y Oncología Pediátrica (SEHOP)

Published in: Clinical and Translational Oncology

Login to get access

Abstract

Introduction

ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.

Methods

The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.

Results

ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.

Discussion

ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.
Literature
2.
go back to reference Cañete Nieto A, Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, et al. Cáncer infantil en España. Estadísticas 1980–2021. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2022. Cañete Nieto A, Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, et al. Cáncer infantil en España. Estadísticas 1980–2021. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2022.
3.
go back to reference Peris-Bonet R. Incidencia y supervivencia del cáncer infantil. In: Madero L, Lassaleta A, Sevilla J, editors. Hematol y Oncol Pediátricas. 3rd ed. Madrid: Ergon; 2015. p. 263–70. Peris-Bonet R. Incidencia y supervivencia del cáncer infantil. In: Madero L, Lassaleta A, Sevilla J, editors. Hematol y Oncol Pediátricas. 3rd ed. Madrid: Ergon; 2015. p. 263–70.
4.
go back to reference Cañete Nieto A, Pardo Romaguera E, Alfonso Comos P, Valero Poveda S, Fernández Férriz A, Porta Cebolla S, et al. Cáncer infantil en España. Estadísticas 1980–2022. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València (Edición preliminar); 2023. Cañete Nieto A, Pardo Romaguera E, Alfonso Comos P, Valero Poveda S, Fernández Férriz A, Porta Cebolla S, et al. Cáncer infantil en España. Estadísticas 1980–2022. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València (Edición preliminar); 2023.
6.
go back to reference Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833–42.CrossRefPubMedPubMedCentral Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833–42.CrossRefPubMedPubMedCentral
8.
go back to reference Nordenmalm S, Tomasi P, Pallidis C. More medicines for children: impact of the EU paediatric regulation. Arch Dis Child. 2018;103:557–64.CrossRefPubMed Nordenmalm S, Tomasi P, Pallidis C. More medicines for children: impact of the EU paediatric regulation. Arch Dis Child. 2018;103:557–64.CrossRefPubMed
11.
go back to reference Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, et al. The role of the “innovative therapies for children with cancer” (ITCC) European consortium. Cancer Treat Rev. 2010;36:328–34.CrossRefPubMed Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, et al. The role of the “innovative therapies for children with cancer” (ITCC) European consortium. Cancer Treat Rev. 2010;36:328–34.CrossRefPubMed
13.
go back to reference Bautista F, Cañete A, Ramírez-Villar GL, et al. Sociedad Española de Hematología y Oncología Pediátrica (SEHOP). ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clin Transl Oncol. 2019;21(12):1763–70. https://doi.org/10.1007/s12094-019-02221-9. (Epub 2019 Oct 9. PMID: 31598904).CrossRefPubMed Bautista F, Cañete A, Ramírez-Villar GL, et al. Sociedad Española de Hematología y Oncología Pediátrica (SEHOP). ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. Clin Transl Oncol. 2019;21(12):1763–70. https://​doi.​org/​10.​1007/​s12094-019-02221-9. (Epub 2019 Oct 9. PMID: 31598904).CrossRefPubMed
14.
go back to reference Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, et al. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol. 2021;23(12):2489–96. https://doi.org/10.1007/s12094-021-02649-y. (Epub 2021 Jun 2 PMID: 34076861).CrossRefPubMed Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, et al. The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). Clin Transl Oncol. 2021;23(12):2489–96. https://​doi.​org/​10.​1007/​s12094-021-02649-y. (Epub 2021 Jun 2 PMID: 34076861).CrossRefPubMed
16.
22.
go back to reference Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2014. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2014.
23.
go back to reference Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15:35–47.CrossRefPubMed Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15:35–47.CrossRefPubMed
Metadata
Title
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer
Authors
Antonio Juan-Ribelles
Francisco Bautista
Adela Cañete
Alba Rubio-San-Simón
Anna Alonso-Saladrigues
Raquel Hladun
Susana Rives
Jose Luís Dapena
Jose María Fernández
Álvaro Lassaletta
Ofelia Cruz
Gemma Ramírez-Villar
Jose Luís Fuster
Cristina Diaz de Heredia
Miguel García-Ariza
Eduardo Quiroga
María del Mar Andrés
Jaime Verdú-Amorós
Antonio Molinés
Blanca Herrero
Mónica López
Catalina Márquez
María Toboso
Frencisco Lendínez
Jose Gómez Sirvent
María Tallón
Guiomar Rodríguez
Tomás Acha
Lucas Moreno
Ana Fernández-Teijeiro
the Sociedad Española de Hematología y Oncología Pediátrica (SEHOP)
Publication date
10-04-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03445-0
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine